DEC 15'03

13:02 No.001 P.01

PTO/SB/97 (08-03)

Approved for two through 07/31/2008, OMB 0851-0031
U.S. Potent and Tradomark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no porsons are required to respond to a collection of information unless if contains a valid OMB control number.

To:

Examiner Konata M. George

Art Unit: 1616

RECEIVED

Fax Number: 703-872-9306

CENTRAL FAX CENTER

DEC | 5 2003

From:

Brian L. Buckwalter, Reg. No. 48,585

Roche Palo Alto LLC,

3431 Hillview Ave., Palo Alto, CA, Fax No.: 650/ 855-5322

Total Pages: 11

## Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on December 15, 2003

Chris Myers

(Typed or printed name of person signing Certificate)

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

#### **Documents Attached:**

S/N 09/966,202, filed September 26, 2001 Inventor Paula Belioni, Docket R0086B-DIV Type of doc. Response to Office Action dated September 15, 2003.

This collection of Information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the

# RECEIVED CENTRAL FAX CENTER

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 1 5 2003

	First Named Inventor	Paula Belloni
Address to: Box AF Commissioner for Patents PO Box 1450 Alexandria, VA 22313	Application Number	09/966,202
	Filing Date	September 26, 2001
	Group Art Unit	1616
	Examiner	George, Konata M.
	Attorney Docket No.	R0086B-DIV
FAX to: 703-872-9306	Title	METHODS FOR THE TREATMENT OF EMPHYSEMA USING 13-CIS- RETINOIC ACID

Commissioner for Patents Alexandria, VA 22313

SIR:

### RESPONSE, AMENDMENT AND REQUEST UNDER 37 CFR §1.604

In response to Office Action dated September 15, 2003, having a shortened statutory period of response set to expire December 15, 2003, please take the following remarks into consideration:

A listing of claims begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.